Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related CPHD
Novartis, Verastem & Cepheid Making Biotech Headlines On Friday
Benzinga's Top Upgrades
Related ABT
3 Companies That Could Be Negatively Impacted By Johnson & Johnson Sale Of Cordis
Mason Hawkins Likes Chemtura, Melco Crown; Doesn't Like Berkshire Hathaway
The Dividend House DGI Portfolio: The Good, The Bad, And The Ugly (Seeking Alpha)

Analysts at Piper Jaffray downgraded Cepheid (NASDAQ: CPHD) from “overweight” to “neutral.” Cepheid's shares closed at $34.09 yesterday. Cepheid's trailing-twelve-month ROE is -12.52%.

Analysts at Deutsche Bank downgraded Abbott Laboratories (NYSE: ABT) from “buy” to “hold.” Abbott's shares closed at $33.27 yesterday. Abbott's PEG ratio is 0.51.

Analysts at Goldman Sachs downgraded Wells Fargo & Company (NYSE: WFC) from “buy” to “neutral.” Wells Fargo's shares closed at $34.76 yesterday. Wells Fargo's trailing-twelve-month profit margin is 23.18%.

Raymond James downgraded First Solar (NASDAQ: FSLR) from “market perform” to “underperform.” First Solar's shares closed at $34.41 yesterday. First Solar's trailing-twelve-month ROA is 2.17%.

Latest Ratings for CPHD

DateFirmActionFromTo
Dec 2014Bank of AmericaUpgradesNeutralBuy
Dec 2014CitigroupMaintainsBuy
Dec 2014OppenheimerMaintainsOutperform

View More Analyst Ratings for CPHD
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (CPHD + ABT)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→